Share on StockTwits

Covidien PLC (NYSE:COV) is scheduled to announce its earnings results on Friday, January 24th. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Covidien PLC (NYSE:COV) last announced its earnings results on Friday, November 8th. The company reported $0.91 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.90 by $0.01. The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter last year, the company posted $1.02 earnings per share. Covidien PLC’s revenue was up 2.4% compared to the same quarter last year. On average, analysts expect Covidien PLC to post $4.00 EPS for the current fiscal year and $4.46 EPS for the next fiscal year.

Covidien PLC (NYSE:COV) opened at 68.09 on Thursday. Covidien PLC has a 52-week low of $53.0496 and a 52-week high of $69.98. The stock’s 50-day moving average is $67.75 and its 200-day moving average is $63.75. The company has a market cap of $30.804 billion and a price-to-earnings ratio of 18.88.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, February 20th. Stockholders of record on Tuesday, January 28th will be given a dividend of 0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Friday, January 24th.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Covidien PLC from $74.00 to $80.00 in a research note to investors on Monday. On a related note, analysts at RBC Capital raised their price target on shares of Covidien PLC from $65.00 to $70.00 in a research note to investors on Tuesday, January 14th. They now have a “sector perform” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Covidien PLC in a research note to investors on Friday, December 13th. They set an “outperform” rating and a $76.00 price target on the stock. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $73.76.

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.